Exact Sciences Corp (Exact Sciences), a subsidiary of Abbott Laboratories, is a molecular diagnostic company that focuses on the early detection and prevention of cancers. The company uses its proprietary stool-based DNA (sDNA) screening technology to identify the presence of cancer and pre-cancer. Its flagship product, Cologuard, is a non-invasive colon cancer screening test. The company operates through a single operating income and generates revenue from three product categories: Screening and Precision Oncology.

Exact Sciences is advancing its pipeline of future screening and diagnostic products, focusing on risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company is developing a colorectal cancer screening blood test, an MRD test leveraging MAESTRO technology, and an MCED test approved for a real-world evidence study. These initiatives are supported by collaborations with Mayo and technologies licensed from institutions like JHU, Broad Institute, Oxford University, Ludwig Institute for Cancer Research, TwinStrand Biosciences, and Freenome. The company has strategic collaborations and licensing agreements with Mayo Foundation for Medical Education and Research, Freenome Holdings, Inc., JHU, Broad Institute, Oxford University, Ludwig Institute for Cancer Research, and TwinStrand Biosciences. The exact number of R&D centers, patents, and pipeline products is not specified in the input text. In FY2025, the company spent US$522.9 million on its R&D activities, which as a percentage of revenue stood at 16.1% and grew 21.2% YoY. As of December 31, 2025, it had 274 issued patents in the US and 965 issued patents outside the US. The company also has several pending patent applications in the US and in other countries.